0.61
+0.0365(+6.36%)
Currency In USD
| Previous Close | 0.57 |
| Open | 0.59 |
| Day High | 0.61 |
| Day Low | 0.58 |
| 52-Week High | 1.79 |
| 52-Week Low | 0.45 |
| Volume | 308,453 |
| Average Volume | 761,243 |
| Market Cap | 37.68M |
| PE | -0.52 |
| EPS | -1.17 |
| Moving Average 50 Days | 0.68 |
| Moving Average 200 Days | 0.84 |
| Change | 0.04 |
If you invested $1000 in Passage Bio, Inc. (PASG) since IPO date, it would be worth $27.48 as of February 05, 2025 at a share price of $0.61. Whereas If you bought $1000 worth of Passage Bio, Inc. (PASG) shares 3 years ago, it would be worth $128.15 as of February 05, 2025 at a share price of $0.61.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates
GlobeNewswire Inc.
Jan 10, 2025 12:00 PM GMT
PBFT02 demonstrated durable, elevated CSF PGRN levels and early evidence of reduction in plasma NfL levels, a disease progression biomarker, compared to published natural history data Evaluating Dose 2, 50% lower than Dose 1, in subsequent FTD-GRN an
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
GlobeNewswire Inc.
Nov 06, 2024 12:00 PM GMT
PHILADELPHIA , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., presiden
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference
GlobeNewswire Inc.
Oct 24, 2024 11:00 AM GMT
Preclinical data demonstrated that an AAV1 vector achieved superior human progranulin levels in the CSF as compared to AAV5 and AAVhu68 (an AAV9 variant) Nonclinical data showed PBFT02 improved lysosomal histopathology and reduced neuroinflammation i